Table 3.
Comparisons of baseline characteristics between the “Helicobacter pylori eradication” and “non‐eradication” groups
| Eradication | Non‐eradication | P‐value | |
|---|---|---|---|
| n | 98 | 99 | |
| Age (years) | 61.9 ± 9.7 | 62.5 ± 9.6 | 0.649 |
| Male (%) | 54.1 | 49.5 | 0.569 |
| BMI (kg/m2) | 27.0 ± 5.3 | 27.1 ± 4.3 | 0.933 |
| Diabetes duration (years) | 11.0 ± 6.9 | 11.2 ± 7.7 | 0.879 |
| Hypertension (%) | 68.4 | 57.1 | 0.139 |
| Statins (%) | 72.4 | 67.7 | 0.534 |
| eGFR (mL/min/1.73 m2) | 70.7 ± 21.9 | 68.7 ± 20.2 | 0.509 |
| ALT (U/L) | 34.6 ± 43.1 | 28.0 ± 13.8 | 0.147 |
| Total cholesterol (mmol/L) | 4.1 ± 0.9 | 4.1 ± 0.8 | 0.853 |
| HDL‐C (mmol/L) | 1.3 ± 0.4 | 1.3 ± 0.4 | 0.967 |
| LDL‐C (mmol/L) | 2.5 ± 0.8 | 2.5 ± 0.8 | 0.602 |
| Triglyceride (mmol/L) | 1.6 ± 0.8 | 1.7 ± 1.1 | 0.404 |
| Fasting plasma glucose (mmol/L) | 8.0 ± 2.2 | 7.3 ± 2.2 | 0.019 |
| A1C (%) | 7.50 ± 1.24 | 7.54 ± 1.40 | 0.844 |
| A1C (mmol/mol) | 58.5 ± 13.6 | 58.9 ± 15.4 | 0.817 |
| Antidiabetic medications | |||
| Insulin (%) | 33.7 | 31.3 | 0.763 |
| Insulin dose/day (Unit) | 37.0 ± 27.5 | 36.7 ± 29.3 | 0.974 |
| Insulin dose/kg/day (Unit) | 0.51 ± 0.42 | 0.54 ± 0.37 | 0.780 |
| OAD classes | 2.0 ± 1.2 | 2.2 ± 1.0 | 0.327 |
| No. participants (percentage) | |||
| 0 class of OAD | 12 (12.2) | 4 (4.0) | * |
| 1 class of OAD | 21 (21.4) | 20 (20.2) | * |
| 2 classes of OAD | 26 (26.5) | 38 (38.4) | * |
| 3 classes of OAD | 32 (32.7) | 29 (29.3) | * |
| 4 classes of OAD | 6 (6.1) | 8 (8.1) | * |
| 5 classes of OAD | 1 (1.0) | 0 (0) | * |
| OAD (%) | 87.8 | 96.0 | 0.040 |
| Metformin (%) | 79.6 | 87.9 | 0.126 |
| Sulfonylureas (%) | 63.3 | 71.7 | 0.226 |
| Glinides (%) | 1.0 | 0 | 0.497 |
| Thiazolidinediones (%) | 24.5 | 24.2 | 1.000 |
| AGIs (%) | 10.2 | 11.1 | 1.000 |
| DPP4is (%) | 24.5 | 22.2 | 0.739 |
Data are expressed as the mean ± standard deviation or percentage. * P‐value by 2 × 6 χ2‐test: not significant. A1C, hemoglobin A1c; AGIs, alpha‐glucosidase inhibitors; ALT, alanine transaminase; BMI, body mass index; DPP‐4is, dipeptidyl peptidase‐4 inhibitors; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; OAD, oral anti‐diabetes drug.